ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum
•Multiple mouse anti-Pfs230 antibodies were generated for ELISA and SMFA tests.•There was a significant correlation between ELISA titer and SMFA activity.•However, ELISA titer alone was a poor predictor of functional activity.•Both IgG2/IgG1 ratio and avidity significantly affected functional activi...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2019-04, Vol.37 (15), p.2073-2078 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2078 |
|---|---|
| container_issue | 15 |
| container_start_page | 2073 |
| container_title | Vaccine |
| container_volume | 37 |
| creator | Miura, Kazutoyo Deng, Bingbing Wu, Yimin Zhou, Luwen Pham, Thao P. Diouf, Ababacar Wu, Chia-Kuei Lee, Shwu-Maan Plieskatt, Jordan L. Morin, Merribeth J. Long, Carole A. |
| description | •Multiple mouse anti-Pfs230 antibodies were generated for ELISA and SMFA tests.•There was a significant correlation between ELISA titer and SMFA activity.•However, ELISA titer alone was a poor predictor of functional activity.•Both IgG2/IgG1 ratio and avidity significantly affected functional activity.
The standard membrane-feeding assay (SMFA) is a functional assay that has been used to inform the development of transmission-blocking vaccines (TBV) against Plasmodium falciparum malaria. For Pfs230, a lead target antigen for TBV development, a few studies have tested either a single anti-Pfs230 polyclonal or monoclonal antibody (one antibody per study) at serial dilutions and showed a dose-dependent response. Further, there have been reports that the SMFA activity of anti-Pfs230 polyclonal and monoclonal antibodies were enhanced in the presence of complement. However, no analysis has been performed with multiple samples, and the impact of anti-Pfs230 antibody titers, IgG subclass profile and avidity were evaluated together in relation to transmission-reducing activity (TRA) by SMFA. In this report, a total of 39 unique anti-Pfs230 IgGs from five different mouse immunization studies were assessed for their ELISA units (EU), IgG2/IgG1 ratio and avidity by ELISA, and the functionality (% transmission-reducing activity, %TRA) by SMFA. The mice were immunized with Pfs230 alone, Pfs230 conjugated to CRM197, or a mixture of unconjugated Pfs230 and CRM197 proteins using Alhydrogel or Montanide ISA720 adjuvants. In all studies, the Pfs230 antigen was from the same source. There was a significant correlation between EU and %TRA (p |
| doi_str_mv | 10.1016/j.vaccine.2019.02.071 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6718089</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X19302889</els_id><sourcerecordid>2189550431</sourcerecordid><originalsourceid>FETCH-LOGICAL-c528t-305e4346af0e18532f5b29b278c0663a38214c72248d3159c850b5b3a59ed8503</originalsourceid><addsrcrecordid>eNqFUstuEzEUHSEQDYVPAFliw4IJfoxnPBuqqiolUiQqARI7y2PfSR3NI9ieoHwWf8gdEipg05Wvdc8593Wy7CWjS0ZZ-W673Btr_QBLTlm9pHxJK_YoWzBViZxLph5nC8rLIi8Y_XaWPYtxSymVgtVPszNBlaRc1Ivs5_V69fmSTINP8S1ZbW5InBrbmRhJMMmPxAyOmL13Ph2IgwShx5qOtNNgMT2YjhgM9nN6bEk_ThGQk3x-20Yu6O-4GZ2HSLaT2yC1ORBDYkJhExzpoW-CGSBvAZwfNgRLmwP54dMducU-euROPWlNZ_3OhKl_nj3BT4QXp_c8-_rh-svVx3z96WZ1dbnOreQq5YJKKERRmpYCU1LwVja8bnilLC1LYYTirLAV54Vygsna4kYa2Qgja3AYi_Ps_VF3NzU9OAtDCqbTu-B7Ew56NF7_mxn8nd6Me11WTFFVo8Cbk0AYv08Qk-59tNB1OC2uSXMuKslrWvCHoUzVUtJCMIS-_g-6HaeAd5hRdYGHVfXcvDyibBhjDNDe982onv2jt_rkHz37R1Ou0T_Ie_X30PesP4ZBwMURALj6vYego_UwWLxdAJu0G_0DJX4BU27bOw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2194085890</pqid></control><display><type>article</type><title>ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Miura, Kazutoyo ; Deng, Bingbing ; Wu, Yimin ; Zhou, Luwen ; Pham, Thao P. ; Diouf, Ababacar ; Wu, Chia-Kuei ; Lee, Shwu-Maan ; Plieskatt, Jordan L. ; Morin, Merribeth J. ; Long, Carole A.</creator><creatorcontrib>Miura, Kazutoyo ; Deng, Bingbing ; Wu, Yimin ; Zhou, Luwen ; Pham, Thao P. ; Diouf, Ababacar ; Wu, Chia-Kuei ; Lee, Shwu-Maan ; Plieskatt, Jordan L. ; Morin, Merribeth J. ; Long, Carole A.</creatorcontrib><description>•Multiple mouse anti-Pfs230 antibodies were generated for ELISA and SMFA tests.•There was a significant correlation between ELISA titer and SMFA activity.•However, ELISA titer alone was a poor predictor of functional activity.•Both IgG2/IgG1 ratio and avidity significantly affected functional activity.
The standard membrane-feeding assay (SMFA) is a functional assay that has been used to inform the development of transmission-blocking vaccines (TBV) against Plasmodium falciparum malaria. For Pfs230, a lead target antigen for TBV development, a few studies have tested either a single anti-Pfs230 polyclonal or monoclonal antibody (one antibody per study) at serial dilutions and showed a dose-dependent response. Further, there have been reports that the SMFA activity of anti-Pfs230 polyclonal and monoclonal antibodies were enhanced in the presence of complement. However, no analysis has been performed with multiple samples, and the impact of anti-Pfs230 antibody titers, IgG subclass profile and avidity were evaluated together in relation to transmission-reducing activity (TRA) by SMFA. In this report, a total of 39 unique anti-Pfs230 IgGs from five different mouse immunization studies were assessed for their ELISA units (EU), IgG2/IgG1 ratio and avidity by ELISA, and the functionality (% transmission-reducing activity, %TRA) by SMFA. The mice were immunized with Pfs230 alone, Pfs230 conjugated to CRM197, or a mixture of unconjugated Pfs230 and CRM197 proteins using Alhydrogel or Montanide ISA720 adjuvants. In all studies, the Pfs230 antigen was from the same source. There was a significant correlation between EU and %TRA (p < 0.0001 by a Spearman rank test) for the anti-Pfs230 IgGs. Notably, multiple linear regression analyses showed that both IgG2/IgG1 ratio and avidity significantly affected %TRA (p = 0.003 to p = 0.014, depending on the models) after adjusting for EU. The results suggest that in addition to antibody titers, IgG2/IgG1 ratio and avidity should each be evaluated to predict the biological activity of anti-Pfs230 antibodies for future vaccine development.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2019.02.071</identifier><identifier>PMID: 30850239</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adjuvants ; Animal models ; Animals ; Anopheles - parasitology ; Antibodies, Protozoan - immunology ; Antibody Affinity ; antigens ; Antigens, Protozoan - classification ; Antigens, Protozoan - immunology ; Assaying ; Avidity ; bioactive properties ; Biological activity ; complement ; Dosage ; dose response ; Enzyme-Linked Immunosorbent Assay ; falciparum malaria ; Feeding ; Female ; IgG subclass ; Immunization ; Immunoglobulin G ; Immunoglobulin G - classification ; Immunoglobulin G - immunology ; Malaria ; Malaria Vaccines - immunology ; Malaria, Falciparum - immunology ; Malaria, Falciparum - prevention & control ; Mice ; Monoclonal antibodies ; Mosquitoes ; Parasites ; Pfs230 ; Plasmodium falciparum ; Plasmodium falciparum - immunology ; Proteins ; Rank tests ; Regression analysis ; Standard membrane-feeding assay ; Transmission-blocking vaccine ; Vaccine development ; Vaccines ; Vector-borne diseases</subject><ispartof>Vaccine, 2019-04, Vol.37 (15), p.2073-2078</ispartof><rights>2019</rights><rights>Copyright © 2019. Published by Elsevier Ltd.</rights><rights>Copyright Elsevier Limited Apr 3, 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c528t-305e4346af0e18532f5b29b278c0663a38214c72248d3159c850b5b3a59ed8503</citedby><cites>FETCH-LOGICAL-c528t-305e4346af0e18532f5b29b278c0663a38214c72248d3159c850b5b3a59ed8503</cites><orcidid>0000-0003-4455-2432 ; 0000-0003-0819-0569</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X19302889$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30850239$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miura, Kazutoyo</creatorcontrib><creatorcontrib>Deng, Bingbing</creatorcontrib><creatorcontrib>Wu, Yimin</creatorcontrib><creatorcontrib>Zhou, Luwen</creatorcontrib><creatorcontrib>Pham, Thao P.</creatorcontrib><creatorcontrib>Diouf, Ababacar</creatorcontrib><creatorcontrib>Wu, Chia-Kuei</creatorcontrib><creatorcontrib>Lee, Shwu-Maan</creatorcontrib><creatorcontrib>Plieskatt, Jordan L.</creatorcontrib><creatorcontrib>Morin, Merribeth J.</creatorcontrib><creatorcontrib>Long, Carole A.</creatorcontrib><title>ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•Multiple mouse anti-Pfs230 antibodies were generated for ELISA and SMFA tests.•There was a significant correlation between ELISA titer and SMFA activity.•However, ELISA titer alone was a poor predictor of functional activity.•Both IgG2/IgG1 ratio and avidity significantly affected functional activity.
The standard membrane-feeding assay (SMFA) is a functional assay that has been used to inform the development of transmission-blocking vaccines (TBV) against Plasmodium falciparum malaria. For Pfs230, a lead target antigen for TBV development, a few studies have tested either a single anti-Pfs230 polyclonal or monoclonal antibody (one antibody per study) at serial dilutions and showed a dose-dependent response. Further, there have been reports that the SMFA activity of anti-Pfs230 polyclonal and monoclonal antibodies were enhanced in the presence of complement. However, no analysis has been performed with multiple samples, and the impact of anti-Pfs230 antibody titers, IgG subclass profile and avidity were evaluated together in relation to transmission-reducing activity (TRA) by SMFA. In this report, a total of 39 unique anti-Pfs230 IgGs from five different mouse immunization studies were assessed for their ELISA units (EU), IgG2/IgG1 ratio and avidity by ELISA, and the functionality (% transmission-reducing activity, %TRA) by SMFA. The mice were immunized with Pfs230 alone, Pfs230 conjugated to CRM197, or a mixture of unconjugated Pfs230 and CRM197 proteins using Alhydrogel or Montanide ISA720 adjuvants. In all studies, the Pfs230 antigen was from the same source. There was a significant correlation between EU and %TRA (p < 0.0001 by a Spearman rank test) for the anti-Pfs230 IgGs. Notably, multiple linear regression analyses showed that both IgG2/IgG1 ratio and avidity significantly affected %TRA (p = 0.003 to p = 0.014, depending on the models) after adjusting for EU. The results suggest that in addition to antibody titers, IgG2/IgG1 ratio and avidity should each be evaluated to predict the biological activity of anti-Pfs230 antibodies for future vaccine development.</description><subject>Adjuvants</subject><subject>Animal models</subject><subject>Animals</subject><subject>Anopheles - parasitology</subject><subject>Antibodies, Protozoan - immunology</subject><subject>Antibody Affinity</subject><subject>antigens</subject><subject>Antigens, Protozoan - classification</subject><subject>Antigens, Protozoan - immunology</subject><subject>Assaying</subject><subject>Avidity</subject><subject>bioactive properties</subject><subject>Biological activity</subject><subject>complement</subject><subject>Dosage</subject><subject>dose response</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>falciparum malaria</subject><subject>Feeding</subject><subject>Female</subject><subject>IgG subclass</subject><subject>Immunization</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin G - classification</subject><subject>Immunoglobulin G - immunology</subject><subject>Malaria</subject><subject>Malaria Vaccines - immunology</subject><subject>Malaria, Falciparum - immunology</subject><subject>Malaria, Falciparum - prevention & control</subject><subject>Mice</subject><subject>Monoclonal antibodies</subject><subject>Mosquitoes</subject><subject>Parasites</subject><subject>Pfs230</subject><subject>Plasmodium falciparum</subject><subject>Plasmodium falciparum - immunology</subject><subject>Proteins</subject><subject>Rank tests</subject><subject>Regression analysis</subject><subject>Standard membrane-feeding assay</subject><subject>Transmission-blocking vaccine</subject><subject>Vaccine development</subject><subject>Vaccines</subject><subject>Vector-borne diseases</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFUstuEzEUHSEQDYVPAFliw4IJfoxnPBuqqiolUiQqARI7y2PfSR3NI9ieoHwWf8gdEipg05Wvdc8593Wy7CWjS0ZZ-W673Btr_QBLTlm9pHxJK_YoWzBViZxLph5nC8rLIi8Y_XaWPYtxSymVgtVPszNBlaRc1Ivs5_V69fmSTINP8S1ZbW5InBrbmRhJMMmPxAyOmL13Ph2IgwShx5qOtNNgMT2YjhgM9nN6bEk_ThGQk3x-20Yu6O-4GZ2HSLaT2yC1ORBDYkJhExzpoW-CGSBvAZwfNgRLmwP54dMducU-euROPWlNZ_3OhKl_nj3BT4QXp_c8-_rh-svVx3z96WZ1dbnOreQq5YJKKERRmpYCU1LwVja8bnilLC1LYYTirLAV54Vygsna4kYa2Qgja3AYi_Ps_VF3NzU9OAtDCqbTu-B7Ew56NF7_mxn8nd6Me11WTFFVo8Cbk0AYv08Qk-59tNB1OC2uSXMuKslrWvCHoUzVUtJCMIS-_g-6HaeAd5hRdYGHVfXcvDyibBhjDNDe982onv2jt_rkHz37R1Ou0T_Ie_X30PesP4ZBwMURALj6vYego_UwWLxdAJu0G_0DJX4BU27bOw</recordid><startdate>20190403</startdate><enddate>20190403</enddate><creator>Miura, Kazutoyo</creator><creator>Deng, Bingbing</creator><creator>Wu, Yimin</creator><creator>Zhou, Luwen</creator><creator>Pham, Thao P.</creator><creator>Diouf, Ababacar</creator><creator>Wu, Chia-Kuei</creator><creator>Lee, Shwu-Maan</creator><creator>Plieskatt, Jordan L.</creator><creator>Morin, Merribeth J.</creator><creator>Long, Carole A.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4455-2432</orcidid><orcidid>https://orcid.org/0000-0003-0819-0569</orcidid></search><sort><creationdate>20190403</creationdate><title>ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum</title><author>Miura, Kazutoyo ; Deng, Bingbing ; Wu, Yimin ; Zhou, Luwen ; Pham, Thao P. ; Diouf, Ababacar ; Wu, Chia-Kuei ; Lee, Shwu-Maan ; Plieskatt, Jordan L. ; Morin, Merribeth J. ; Long, Carole A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c528t-305e4346af0e18532f5b29b278c0663a38214c72248d3159c850b5b3a59ed8503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adjuvants</topic><topic>Animal models</topic><topic>Animals</topic><topic>Anopheles - parasitology</topic><topic>Antibodies, Protozoan - immunology</topic><topic>Antibody Affinity</topic><topic>antigens</topic><topic>Antigens, Protozoan - classification</topic><topic>Antigens, Protozoan - immunology</topic><topic>Assaying</topic><topic>Avidity</topic><topic>bioactive properties</topic><topic>Biological activity</topic><topic>complement</topic><topic>Dosage</topic><topic>dose response</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>falciparum malaria</topic><topic>Feeding</topic><topic>Female</topic><topic>IgG subclass</topic><topic>Immunization</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin G - classification</topic><topic>Immunoglobulin G - immunology</topic><topic>Malaria</topic><topic>Malaria Vaccines - immunology</topic><topic>Malaria, Falciparum - immunology</topic><topic>Malaria, Falciparum - prevention & control</topic><topic>Mice</topic><topic>Monoclonal antibodies</topic><topic>Mosquitoes</topic><topic>Parasites</topic><topic>Pfs230</topic><topic>Plasmodium falciparum</topic><topic>Plasmodium falciparum - immunology</topic><topic>Proteins</topic><topic>Rank tests</topic><topic>Regression analysis</topic><topic>Standard membrane-feeding assay</topic><topic>Transmission-blocking vaccine</topic><topic>Vaccine development</topic><topic>Vaccines</topic><topic>Vector-borne diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miura, Kazutoyo</creatorcontrib><creatorcontrib>Deng, Bingbing</creatorcontrib><creatorcontrib>Wu, Yimin</creatorcontrib><creatorcontrib>Zhou, Luwen</creatorcontrib><creatorcontrib>Pham, Thao P.</creatorcontrib><creatorcontrib>Diouf, Ababacar</creatorcontrib><creatorcontrib>Wu, Chia-Kuei</creatorcontrib><creatorcontrib>Lee, Shwu-Maan</creatorcontrib><creatorcontrib>Plieskatt, Jordan L.</creatorcontrib><creatorcontrib>Morin, Merribeth J.</creatorcontrib><creatorcontrib>Long, Carole A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miura, Kazutoyo</au><au>Deng, Bingbing</au><au>Wu, Yimin</au><au>Zhou, Luwen</au><au>Pham, Thao P.</au><au>Diouf, Ababacar</au><au>Wu, Chia-Kuei</au><au>Lee, Shwu-Maan</au><au>Plieskatt, Jordan L.</au><au>Morin, Merribeth J.</au><au>Long, Carole A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2019-04-03</date><risdate>2019</risdate><volume>37</volume><issue>15</issue><spage>2073</spage><epage>2078</epage><pages>2073-2078</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•Multiple mouse anti-Pfs230 antibodies were generated for ELISA and SMFA tests.•There was a significant correlation between ELISA titer and SMFA activity.•However, ELISA titer alone was a poor predictor of functional activity.•Both IgG2/IgG1 ratio and avidity significantly affected functional activity.
The standard membrane-feeding assay (SMFA) is a functional assay that has been used to inform the development of transmission-blocking vaccines (TBV) against Plasmodium falciparum malaria. For Pfs230, a lead target antigen for TBV development, a few studies have tested either a single anti-Pfs230 polyclonal or monoclonal antibody (one antibody per study) at serial dilutions and showed a dose-dependent response. Further, there have been reports that the SMFA activity of anti-Pfs230 polyclonal and monoclonal antibodies were enhanced in the presence of complement. However, no analysis has been performed with multiple samples, and the impact of anti-Pfs230 antibody titers, IgG subclass profile and avidity were evaluated together in relation to transmission-reducing activity (TRA) by SMFA. In this report, a total of 39 unique anti-Pfs230 IgGs from five different mouse immunization studies were assessed for their ELISA units (EU), IgG2/IgG1 ratio and avidity by ELISA, and the functionality (% transmission-reducing activity, %TRA) by SMFA. The mice were immunized with Pfs230 alone, Pfs230 conjugated to CRM197, or a mixture of unconjugated Pfs230 and CRM197 proteins using Alhydrogel or Montanide ISA720 adjuvants. In all studies, the Pfs230 antigen was from the same source. There was a significant correlation between EU and %TRA (p < 0.0001 by a Spearman rank test) for the anti-Pfs230 IgGs. Notably, multiple linear regression analyses showed that both IgG2/IgG1 ratio and avidity significantly affected %TRA (p = 0.003 to p = 0.014, depending on the models) after adjusting for EU. The results suggest that in addition to antibody titers, IgG2/IgG1 ratio and avidity should each be evaluated to predict the biological activity of anti-Pfs230 antibodies for future vaccine development.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>30850239</pmid><doi>10.1016/j.vaccine.2019.02.071</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-4455-2432</orcidid><orcidid>https://orcid.org/0000-0003-0819-0569</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2019-04, Vol.37 (15), p.2073-2078 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6718089 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adjuvants Animal models Animals Anopheles - parasitology Antibodies, Protozoan - immunology Antibody Affinity antigens Antigens, Protozoan - classification Antigens, Protozoan - immunology Assaying Avidity bioactive properties Biological activity complement Dosage dose response Enzyme-Linked Immunosorbent Assay falciparum malaria Feeding Female IgG subclass Immunization Immunoglobulin G Immunoglobulin G - classification Immunoglobulin G - immunology Malaria Malaria Vaccines - immunology Malaria, Falciparum - immunology Malaria, Falciparum - prevention & control Mice Monoclonal antibodies Mosquitoes Parasites Pfs230 Plasmodium falciparum Plasmodium falciparum - immunology Proteins Rank tests Regression analysis Standard membrane-feeding assay Transmission-blocking vaccine Vaccine development Vaccines Vector-borne diseases |
| title | ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T06%3A44%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ELISA%20units,%20IgG%20subclass%20ratio%20and%20avidity%20determined%20functional%20activity%20of%20mouse%20anti-Pfs230%20antibodies%20judged%20by%20a%20standard%20membrane-feeding%20assay%20with%20Plasmodium%20falciparum&rft.jtitle=Vaccine&rft.au=Miura,%20Kazutoyo&rft.date=2019-04-03&rft.volume=37&rft.issue=15&rft.spage=2073&rft.epage=2078&rft.pages=2073-2078&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2019.02.071&rft_dat=%3Cproquest_pubme%3E2189550431%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2194085890&rft_id=info:pmid/30850239&rft_els_id=S0264410X19302889&rfr_iscdi=true |